Fig. 3

Down-regulation of miR-17-92 and miR-106b-25 contributed to antitumor activity of triptolide in HepG2 cells. a qRT-PCR was performed to compare the expression of pri-miR-17-92 and pri- miR-106b-25 in LO2 and HepG2 cells. b Knockdown of miR-106b-25 using antisense oligonucleotides reduced HepG2 cell proliferation. c Ectopic expression of miR-17-92 and miR-106b-25 with corresponding expression vector enhanced the proliferation of LO2 cells. d and e Triptolide up-regulated the expression of PTEN and BIM in HepG2 cells and implanted tumors. f Forced expression of miR-17-92, miR-106b-25, or the combination of miR-17-92 and miR-106b-25 protected HepG2 cells from triptolide-induced apoptosis. The bars represented mean ± standard error of the mean, n ≥ 3. *P<.05, **P<.01 (t test)